Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KDR2-2 in Healthy Volunteers
NCT04620109Phase 1Unknown
- Sponsor
- Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KDR2-2 in corneal neovascularization (CNV) (9 arms), sponsored by Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd. Primary endpoints: Incidence of AE and SAE reporting at 31 days, Vital Signs Parameters at 8 days and 8 more. Status: unknown.
02
Drugs
KDR2-2
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT04620109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620109.